P2Y12 inhibitors

1. P2Y12 inhibitors have no effect on colorectal cancer incidence in humans.

   “We did not observe an association between P2Y12 inhibitor use and CRC incidence.”

   HumansAtherosclerotic cardiovascular disease≥84 consecutive Defined Daily DosesMedian follow-up 5.1 yearsn = 334,882

   Platelet P2Y12 inhibitor use and risk of colorectal cancer incidence and colorectal cancer-related mortality: a Swedish registry-based cohort study

   BMC gastroenterology·12 Oct 2026

More on Colorectal cancer incidence

1. P2Y12 inhibitors are associated with colorectal cancer-related mortality in humans (HR 0.73 (95% CI, 0.60-0.89)).

   “a longer duration of P2Y12 inhibitor use was associated with lower CRC-related mortality.”

   HumansAtherosclerotic cardiovascular disease; compared with non-users336-671 cDDDs

   Platelet P2Y12 inhibitor use and risk of colorectal cancer incidence and colorectal cancer-related mortality: a Swedish registry-based cohort study

   BMC gastroenterology·12 Oct 2026